| Company Name | Exchange | Ticker | Last Price | Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Parex Resources Inc | TSX | PXT | 12.54 | 1,384.3 | Re-initiate with top pick | Darren B Engels | FirstEnergy Capital Corp | 17.00 | 35.6% |
| Northern Frontier Corp | TSXV | FFF | 3.00 | 33.7 | Downgrade to hold from buy | Brian D Pow | Acumen Capital Finance | 3.70 | 23.3% |
| Crown Point Energy Inc | TSXV | CWV | 0.35 | 36.6 | Downgrade to hold from speculative buy | Christopher Brown | Canaccord Genuity Corp | 0.50 | 42.9% |
FirstEnergy Capital Corp re-initiated coverage on Parex Resources Inc (TSX: PXT), engaged in oil and natural gas exploration, development and production, with a top pick rating assigning a 12-month price target of C$17.00, indicating an upside of 35.6% from current levels.
Acumen Capital Finance downgraded Northern Frontier Corp (TSXV: FFF), a capital pool company focused on creating a large resource maintenance and essential services business through a buy and build growth strategy, to hold from buy lowering its price target to C$3.70 from C$5.50, indicating an upside of 23.3% from current levels.
Crown Point Energy Inc (TSXV: CWV), a Canada-based oil and gas exploration and development company, engaged in developing its level of reserves, production and opportunities present on its seven concessions, was downgraded to hold from speculative buy at Canaccord Genuity Corp reducing its price target to C$0.50 from the earlier target of C$1.50, indicating an upside of 42.9% from current levels.
| Company Name | Exchange | Ticker | Last Price |
Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Coeur Mining Inc | NYSE | CDE | 8.69 | 899.6 | Upgrade to market perform from underperform | Andrew Kaip | BMO Capital Markets | 9.50 | 9.3% |
| InnerWorkings Inc | NASDAQ | INWK | 7.83 | 404.5 | Upgrade to buy from hold | George F Sutton | Craig-Hallum Capital Group LLC | 10.00 | 27.7% |
| Kraton Performance Polymers Inc | NYSE | KRA | 21.53 | 705.7 | Upgrade to outperform from market perform | Edward H Yang | Oppenheimer & Co | 30.00 | 39.3% |
| LeMaitre Vascular Inc | NASDAQ | LMAT | 7.92 | 135.2 | Initiate with buy | Frederick A Wise | Stifel | 11.00 | 38.9% |
| Dot Hill Systems Corp | NASDAQ | HILL | 4.59 | 275.4 | Initiate with buy | Matthew Galinko | Sidoti & Company LLC | 6.00 | 30.7% |
| Enanta Pharmaceuticals Inc | NASDAQ | ENTA | 43.43 | 805.1 | Downgrade to neutral from outperform | Brian P Skorney | Robert W. Baird & Co | 41.00 | -5.6% |
BMO Capital Markets upgraded Coeur Mining Inc (NYSE: CDE), engaged in exploring, developing, operating silver and gold mining properties, to market perform from underperform increasing its price target to $9.50 from $7.00, indicating an upside of 9.3% from current levels.
InnerWorkings Inc (NASDAQ: INWK), a provider of global print management and promotional solutions to corporate clients across a ranges of industries, was upgraded to buy from hold at Craig-Hallum Capital Group LLC raising its price target to $10.00 from $9.00, indicating an upside potential of 27.7% from current levels.
Oppenheimer & Co upgraded Kraton Performance Polymers Inc (NYSE: KRA), a producer of styrenic block copolymers (SBCs) and other engineered polymers, to outperform from market perform with a price target of $30.00, indicating an upside of 39.3% from current levels.
Stifel initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT), a global provider of medical devices and implants for the treatment of peripheral vascular disease, with a buy rating assigning a 12-month price target of $11.00, indicating an upside of 38.9% from current levels.
Coverage on Dot Hill Systems Corp (NASDAQ: HILL), engaged in designing, manufacturing and marketing a range of software and hardware storage systems for the entry and mid-range storage markets, was initiated with a buy rating at Sidoti & Company LLC with a 12-month price target of $6.00, indicating an upside of 30.7% from current levels.
Robert W. Baird & Co downgraded Enanta Pharmaceuticals Inc (NASDAQ: ENTA), a research and development-focused biotechnology company, to neutral from outperform with a price target of $41.00, indicating a downside of 5.6% from current levels.
